Charles River Laboratories International, Inc. Common Stock (CRL)
152.84
-13.14 (-7.92%)
NYSE · Last Trade: Feb 12th, 1:53 PM EST
Detailed Quote
Previous Close
165.98
Open
157.49
Bid
152.42
Ask
152.93
Day's Range
148.34 - 162.62
52 Week Range
91.86 - 228.88
Volume
1,727,771
Market Cap
7.70B
PE Ratio (TTM)
-101.22
EPS (TTM)
-1.5
Dividend & Yield
N/A (N/A)
1 Month Average Volume
788,249
Chart
About Charles River Laboratories International, Inc. Common Stock (CRL)
Charles River Laboratories International is a global provider of laboratory services that support the pharmaceutical, biotechnology, and medical device industries. The company offers a comprehensive suite of research and development solutions, including essential support for drug discovery, safety assessment, and manufacturing. By providing innovative tools and technologies, as well as expertise in areas such as toxicology and genetic testing, Charles River plays a critical role in advancing biomedical research and helping clients develop and bring new therapies to market efficiently and effectively. Read More
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Charles River Laboratories has had an impressive run over the past six months as its shares have beaten the S&P 500 by 20.5%. The stock now trades at $189.18, marking a 27% gain. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets.
But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
Wall Street has issued downbeat forecasts for the stocks in this article.
These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2025 financial results and provide 2026 guidance on Wednesday, February 18th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, February 18th, at 8:30 a.m. ET.
Charles River Laboratories International, Inc. (NYSE: CRL) and Gazi University Faculty of Medicine, today announced a gene therapy contract development and manufacturing organization (CDMO) collaboration, providing plasmid DNA for AAV production and in vitro efficacy studies.
Charles River Laboratories International, Inc. (NYSE: CRL) today announced two planned acquisitions of K.F. (Cambodia) Ltd. and PathoQuest SAS; the addition of Dr. Namandjé N. Bumpus as Chief Scientific and Innovation Officer; and is also providing an update on recent business trends and a preliminary 2026 outlook at the J.P. Morgan 44th Annual Healthcare Conference.
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that James C. (Jim) Foster, Chair, President, and Chief Executive Officer (CEO), plans to retire, effective on May 5, 2026 at the conclusion of the 2026 Annual Meeting of Shareholders. The Company’s Board of Directors (Board) has unanimously appointed Birgit Girshick, current Executive Vice President and Chief Operating Officer (COO), as the next CEO, concurrent with Mr. Foster’s planned retirement in May. Ms. Girshick has also been nominated by the Board to be a Director effective at the 2026 Annual Meeting.
In the complex ecosystem of modern medicine, few companies carry as much institutional weight—or stir as much controversy—as Charles River Laboratories International, Inc. (NYSE: CRL). As of December 23, 2025, Charles River stands as the indispensable backbone of the global pharmaceutical industry. It is a company that has, remarkably, participated in the development of over [...]
The stocks featured in this article have all approached their 52-week highs.
When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Shares of lab services company Charles River Laboratories (NYSE:CRL)
jumped 2.9% in the afternoon session after BofA Securities upgraded the stock and the U.S. Securities and Exchange Commission concluded its investigation into the company with no enforcement action.
Stay updated with the movements of the S&P500 index in the middle of the day on Monday. Discover which stocks are leading as top gainers and losers in today's session.
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the second cohort of its Cell & Gene Therapy Incubator Program (CIP). Launched in December 2024, with the inaugural cohort announced in April 2025, the program provides early-stage biotechnology pioneers with access to extensive scientific and commercial expertise, as well as a comprehensive ecosystem of discovery, development, and manufacturing capabilities, to expedite the development of technologies and life-changing therapies for patients in need.
Even if a company is profitable, it doesn’t always mean it’s a great investment.
Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Shares of lab services company Charles River Laboratories (NYSE:CRL)
jumped 6.1% in the afternoon session after the company provided an encouraging business update at an investor conference, highlighting positive demand trends.
Stay updated with the movements of the S&P500 index in the middle of the day on Wednesday. Discover which stocks are leading as top gainers and losers in today's session.
Let's have a look at what is happening on the US markets before the opening bell on Wednesday. Below you can find the top S&P500 gainers and losers in today's pre-market session.
